tiprankstipranks
Ultragenyx Pharmaceutical (DE:UP0)
FRANKFURT:UP0
Germany Market
UP0
Ultragenyx Pharmaceutical
RESEARCH TOOLSreports

Ultragenyx Pharmaceutical (UP0) Stock Forecast & Price Target

2 Followers
See the Price Targets and Ratings of:

UP0 Analyst Ratings

Strong Buy
16Ratings
Strong Buy
14 Buy
2 Hold
0 Sell
Based on 16 analysts giving stock ratings to
Ultragenyx
Pharmaceutical
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

UP0 Stock 12 Month Forecast

Average Price Target

€46.53
▲(97.73% Upside)
Based on 16 Wall Street analysts offering 12 month price targets for Ultragenyx Pharmaceutical in the last 3 months. The average price target is €46.53 with a high forecast of €83.26 and a low forecast of €23.42. The average price target represents a 97.73% change from the last price of €23.53.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"16":"€16","33":"€33","50":"€50","67":"€67","84":"€84"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":83.26459679999999,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€83.26</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":46.52657157499999,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€46.53</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23.41816785,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€23.42</span>\n  </div></div>","useHTML":true}}],"tickPositions":[16,33,50,67,84],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.52,27.19266129230769,31.865322584615384,36.53798387692308,41.21064516923077,45.88330646153847,50.555967753846154,55.22862904615384,59.901290338461536,64.57395163076923,69.24661292307692,73.91927421538462,78.59193550769231,{"y":83.26459679999999,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.52,24.366659351923076,26.213318703846152,28.05997805576923,29.906637407692305,31.75329675961538,33.59995611153846,35.446615463461534,37.293274815384606,39.139934167307686,40.986593519230766,42.83325287115384,44.67991222307691,{"y":46.52657157499999,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.52,22.589089834615383,22.65817966923077,22.727269503846152,22.79635933846154,22.86544917307692,22.934539007692308,23.00362884230769,23.072718676923078,23.14180851153846,23.210898346153847,23.27998818076923,23.349078015384617,{"y":23.41816785,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":23.8,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.6,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.4,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.2,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.6,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.7,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.5,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.9,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.39,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.37,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.89,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.52,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€83.26Average Price Target€46.53Lowest Price Target€23.42
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Canaccord Genuity Analyst forecast on DE:UP0
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
€68.52→€70.25
Buy
198.57%
Upside
Reiterated
08/05/26
Ultragenyx price target raised to $81 from $79 at CanaccordUltragenyx price target raised to $81 from $79 at Canaccord
Citi Analyst forecast on DE:UP0
Yigal Nochomovitz
Citi
Citi
€39.03
Buy
65.87%
Upside
Reiterated
08/05/26
Analysts Offer Insights on Healthcare Companies: Pfizer (NYSE: PFE), Ultragenyx Pharmaceutical (NASDAQ: RARE) and Allogene Therapeutics (NASDAQ: ALLO)
Barclays Analyst forecast on DE:UP0
Eliana Merle
Barclays
Barclays
€37.3
Buy
58.50%
Upside
Reiterated
08/05/26
Barclays Sticks to Its Buy Rating for Ultragenyx Pharmaceutical (RARE)
Wells Fargo Analyst forecast on DE:UP0
Benjamin Burnett
Wells Fargo
Wells Fargo
€40.76→€39.03
Buy
65.87%
Upside
Assigned
08/05/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Spyre Therapeutics (NASDAQ: SYRE), Ultragenyx Pharmaceutical (NASDAQ: RARE) and Bruker (NASDAQ: BRKR)
RBC Capital Analyst forecast on DE:UP0
Luca Issi
RBC Capital
RBC Capital
€34.69
Buy
47.44%
Upside
Reiterated
08/05/26
Analysts' Top Healthcare Picks: Rhythm Pharmaceuticals (RYTM), Ultragenyx Pharmaceutical (RARE)
TD Cowen Analyst forecast on DE:UP0
Yaron Werber
TD Cowen
TD Cowen
€42.5
Buy
80.62%
Upside
Assigned
08/04/26
Ultragenyx: Strong Q2 Beat, Clear Path to FY27 Profitability and Catalyst-Rich 2H26 Support Buy Rating
Cantor Fitzgerald Analyst forecast on DE:UP0
Kristen Kluska
Cantor Fitzgerald
Cantor Fitzgerald
€83.26
Buy
253.87%
Upside
Reiterated
08/04/26
Cantor Fitzgerald Remains a Buy on Ultragenyx Pharmaceutical (RARE)
Morgan Stanley Analyst forecast on DE:UP0
Maxwell Skor
Morgan Stanley
Morgan Stanley
€58.11
Buy
146.97%
Upside
Reiterated
08/04/26
Ultragenyx: Strong Commercial Momentum and Diversified Late-Stage Pipeline Support Buy Rating and Unchanged $67 Price Target
Guggenheim Analyst forecast on DE:UP0
Debjit Chattopadhyay
Guggenheim
Guggenheim
€37.3→€30.36
Buy
29.01%
Upside
Reiterated
08/03/26
Analysts' Top Healthcare Picks: Oric Pharmaceuticals (ORIC), AbbVie (ABBV)
Wedbush Analyst forecast on DE:UP0
Laura Chico
Wedbush
Wedbush
―
Hold
―
Reiterated
07/31/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Alnylam Pharma (NASDAQ: ALNY), Ultragenyx Pharmaceutical (NASDAQ: RARE) and Bausch Health Companies (NYSE: BHC)
Bank of America Securities Analyst forecast on DE:UP0
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
―
Buy
―
Reiterated
07/27/26
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (NASDAQ: RARE) and Danaher (NYSE: DHR)
Goldman Sachs Analyst forecast on DE:UP0
Salveen Richter
Goldman Sachs
Goldman Sachs
€21.68→€23.42
Hold
-0.48%
Downside
Reiterated
07/20/26
Goldman Sachs Sticks to Its Hold Rating for Ultragenyx Pharmaceutical (RARE)
J.P. Morgan Analyst forecast on DE:UP0
Anupam Rama
J.P. Morgan
J.P. Morgan
€62.45
Buy
165.40%
Upside
Reiterated
07/07/26
Ultragenyx: Favorable Risk-Reward Ahead of GTX-102 ASPIRE Readout, Analyst Reiterates Buy and $72 Price Target
Evercore ISI Analyst forecast on DE:UP0
Gavin Clark-Gartner
Evercore ISI
Evercore ISI
€29.49→€28.62
Buy
21.64%
Upside
Reiterated
05/11/26
Ultragenyx price target lowered to $33 from $34 at Evercore ISIUltragenyx price target lowered to $33 from $34 at Evercore ISI
H.C. Wainwright Analyst forecast on DE:UP0
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
€43.37
Buy
84.31%
Upside
Reiterated
05/11/26
Analysts Offer Insights on Healthcare Companies: Kodiak Sciences (NASDAQ: KOD), IN8bio (NASDAQ: INAB) and Ultragenyx Pharmaceutical (NASDAQ: RARE)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Canaccord Genuity Analyst forecast on DE:UP0
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
€68.52→€70.25
Buy
198.57%
Upside
Reiterated
08/05/26
Ultragenyx price target raised to $81 from $79 at CanaccordUltragenyx price target raised to $81 from $79 at Canaccord
Citi Analyst forecast on DE:UP0
Yigal Nochomovitz
Citi
Citi
€39.03
Buy
65.87%
Upside
Reiterated
08/05/26
Analysts Offer Insights on Healthcare Companies: Pfizer (NYSE: PFE), Ultragenyx Pharmaceutical (NASDAQ: RARE) and Allogene Therapeutics (NASDAQ: ALLO)
Barclays Analyst forecast on DE:UP0
Eliana Merle
Barclays
Barclays
€37.3
Buy
58.50%
Upside
Reiterated
08/05/26
Barclays Sticks to Its Buy Rating for Ultragenyx Pharmaceutical (RARE)
Wells Fargo Analyst forecast on DE:UP0
Benjamin Burnett
Wells Fargo
Wells Fargo
€40.76→€39.03
Buy
65.87%
Upside
Assigned
08/05/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Spyre Therapeutics (NASDAQ: SYRE), Ultragenyx Pharmaceutical (NASDAQ: RARE) and Bruker (NASDAQ: BRKR)
RBC Capital Analyst forecast on DE:UP0
Luca Issi
RBC Capital
RBC Capital
€34.69
Buy
47.44%
Upside
Reiterated
08/05/26
Analysts' Top Healthcare Picks: Rhythm Pharmaceuticals (RYTM), Ultragenyx Pharmaceutical (RARE)
TD Cowen Analyst forecast on DE:UP0
Yaron Werber
TD Cowen
TD Cowen
€42.5
Buy
80.62%
Upside
Assigned
08/04/26
Ultragenyx: Strong Q2 Beat, Clear Path to FY27 Profitability and Catalyst-Rich 2H26 Support Buy Rating
Cantor Fitzgerald Analyst forecast on DE:UP0
Kristen Kluska
Cantor Fitzgerald
Cantor Fitzgerald
€83.26
Buy
253.87%
Upside
Reiterated
08/04/26
Cantor Fitzgerald Remains a Buy on Ultragenyx Pharmaceutical (RARE)
Morgan Stanley Analyst forecast on DE:UP0
Maxwell Skor
Morgan Stanley
Morgan Stanley
€58.11
Buy
146.97%
Upside
Reiterated
08/04/26
Ultragenyx: Strong Commercial Momentum and Diversified Late-Stage Pipeline Support Buy Rating and Unchanged $67 Price Target
Guggenheim Analyst forecast on DE:UP0
Debjit Chattopadhyay
Guggenheim
Guggenheim
€37.3→€30.36
Buy
29.01%
Upside
Reiterated
08/03/26
Analysts' Top Healthcare Picks: Oric Pharmaceuticals (ORIC), AbbVie (ABBV)
Wedbush Analyst forecast on DE:UP0
Laura Chico
Wedbush
Wedbush
―
Hold
―
Reiterated
07/31/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Alnylam Pharma (NASDAQ: ALNY), Ultragenyx Pharmaceutical (NASDAQ: RARE) and Bausch Health Companies (NYSE: BHC)
Bank of America Securities Analyst forecast on DE:UP0
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
―
Buy
―
Reiterated
07/27/26
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (NASDAQ: RARE) and Danaher (NYSE: DHR)
Goldman Sachs Analyst forecast on DE:UP0
Salveen Richter
Goldman Sachs
Goldman Sachs
€21.68→€23.42
Hold
-0.48%
Downside
Reiterated
07/20/26
Goldman Sachs Sticks to Its Hold Rating for Ultragenyx Pharmaceutical (RARE)
J.P. Morgan Analyst forecast on DE:UP0
Anupam Rama
J.P. Morgan
J.P. Morgan
€62.45
Buy
165.40%
Upside
Reiterated
07/07/26
Ultragenyx: Favorable Risk-Reward Ahead of GTX-102 ASPIRE Readout, Analyst Reiterates Buy and $72 Price Target
Evercore ISI Analyst forecast on DE:UP0
Gavin Clark-Gartner
Evercore ISI
Evercore ISI
€29.49→€28.62
Buy
21.64%
Upside
Reiterated
05/11/26
Ultragenyx price target lowered to $33 from $34 at Evercore ISIUltragenyx price target lowered to $33 from $34 at Evercore ISI
H.C. Wainwright Analyst forecast on DE:UP0
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
€43.37
Buy
84.31%
Upside
Reiterated
05/11/26
Analysts Offer Insights on Healthcare Companies: Kodiak Sciences (NASDAQ: KOD), IN8bio (NASDAQ: INAB) and Ultragenyx Pharmaceutical (NASDAQ: RARE)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
MLYSMineralys Therapeutics, Inc.
ZURAZura Bio
TNYATenaya Therapeutics
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ultragenyx Pharmaceutical

3 Months
Joon LeeTruist Financial
Success Rate
13/23 ratings generated profit
57%
Average Return
+1.75%
Copying Joon Lee's trades and holding each position for 3 Months would result in 56.52% of your transactions generating a profit, with an average return of +1.75% per trade.
1 Year
Yigal NochomovitzCiti
Success Rate
9/20 ratings generated profit
45%
Average Return
-0.73%
Copying Yigal Nochomovitz's trades and holding each position for 1 Year would result in 45.00% of your transactions generating a profit, with an average return of -0.73% per trade.
2 Years
Yaron WerberTD Cowen
Success Rate
11/32 ratings generated profit
34%
Average Return
-5.42%
Copying Yaron Werber's trades and holding each position for 2 Years would result in 34.38% of your transactions generating a profit, with an average return of -5.42% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

UP0 Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
20
18
16
14
11
Buy
6
3
3
4
3
Hold
2
2
1
4
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
28
23
20
22
17
In the current month, UP0 has received 14 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. UP0 average Analyst price target in the past 3 months is 46.53.
Each month's total comprises the sum of three months' worth of ratings.

UP0 Financial Forecast

UP0 Earnings Forecast

Next quarter’s earnings estimate for UP0 is -€0.88 with a range of -€1.12 to €0.02. The previous quarter’s EPS was -€0.78. UP0 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 40.74% of the time in the same period. In the last calendar year UP0 has Performed in-line its overall industry.
Next quarter’s earnings estimate for UP0 is -€0.88 with a range of -€1.12 to €0.02. The previous quarter’s EPS was -€0.78. UP0 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 40.74% of the time in the same period. In the last calendar year UP0 has Performed in-line its overall industry.

UP0 Sales Forecast

Next quarter’s sales forecast for UP0 is €159.15M with a range of €147.01M to €168.42M. The previous quarter’s sales results were €185.61M. UP0 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 39.76% of the time in the same period. In the last calendar year UP0 has Performed in-line its overall industry.
Next quarter’s sales forecast for UP0 is €159.15M with a range of €147.01M to €168.42M. The previous quarter’s sales results were €185.61M. UP0 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 39.76% of the time in the same period. In the last calendar year UP0 has Performed in-line its overall industry.

UP0 Stock Forecast FAQ

What is DE:UP0’s average 12-month price target, according to analysts?
Based on analyst ratings, Ultragenyx Pharmaceutical’s 12-month average price target is 46.53.
    What is DE:UP0’s upside potential, based on the analysts’ average price target?
    Ultragenyx Pharmaceutical has 97.73% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Ultragenyx Pharmaceutical a Buy, Sell or Hold?
          Ultragenyx Pharmaceutical has a consensus rating of Strong Buy, which is based on 14 buy ratings, 2 hold ratings and 0 sell ratings.
            What is Ultragenyx Pharmaceutical’s share price target?
            The average share price target for Ultragenyx Pharmaceutical is 46.53. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €83.26 ,and the lowest forecast is €23.42. The average share price target represents 97.73% Increase from the current price of €23.53.
              What do analysts say about Ultragenyx Pharmaceutical?
              Ultragenyx Pharmaceutical’s analyst rating consensus is a Strong Buy. This is based on the ratings of 16 Wall Streets Analysts.
                How can I buy shares of Ultragenyx Pharmaceutical?
                To buy shares of DE:UP0, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.